Fog City Capital

Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods

Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods

Ad-Lib.io is a digital creative technology and service business based in the UK, specializing in the automation and management of creative assets for digital advertising. The company partners with platforms like Facebook and DoubleClick to enhance the efficiency of digital creative deployment. Ad-Lib.io does not engage in media buying; instead, it focuses on delivering optimized creative solutions. Its offerings include dynamic video capabilities, A/B testing, and an optimization algorithm, all designed to streamline workflows and improve campaign performance. The platform is engineered to save clients significant time—up to 46%—and enhance performance by as much as 80%, providing a comprehensive service that supports global brands in their digital advertising efforts.

Ad-Lib.io is a digital creative technology and service business based in the UK, specializing in the automation and management of creative assets for digital advertising. The company partners with platforms like Facebook and DoubleClick to enhance the efficiency of digital creative deployment. Ad-Lib.io does not engage in media buying; instead, it focuses on delivering optimized creative solutions. Its offerings include dynamic video capabilities, A/B testing, and an optimization algorithm, all designed to streamline workflows and improve campaign performance. The platform is engineered to save clients significant time—up to 46%—and enhance performance by as much as 80%, providing a comprehensive service that supports global brands in their digital advertising efforts.

Visual IQ is a leading provider of cross-channel marketing attribution software, established in 2006. The company offers its SaaS-based IQ Intelligence Suite, which delivers in-depth insights into cross-channel marketing performance by analyzing complex data sets. This platform provides actionable recommendations and optimized media plans that enhance the effectiveness of marketing strategies across both online and offline channels, thereby increasing return on investment. Visual IQ utilizes advanced multi-dimensional fractional attribution science and predictive analytics to help marketers identify and capitalize on improvement opportunities. The company's contributions to the field have been recognized through various awards, including The Drum's Digital Trading Award for Best Attribution Solution and the ASPY Award for Best Data or Analytics Solution. Visual IQ is also actively involved in industry organizations, serving on councils and committees related to advertising technology and data analytics.

Cianna Medical, Inc. is a women’s health company focused on innovative solutions for the treatment of early-stage breast cancer. Based in Aliso Viejo, California, the company develops advanced medical technologies designed to enhance breast conservation therapy. Its primary products include SAVI SCOUT, a wire-free radar localization system that assists in accurately locating breast tumors, and SAVI Brachy, which delivers targeted radiation therapy to minimize damage to surrounding healthy tissue. Additionally, Cianna Medical provides BrachyBytes, an e-newsletter that shares insights and expert interviews on breast brachytherapy. Incorporated in 2007, the company aims to expand access to effective treatment options for women diagnosed with breast cancer, improving their chances for successful outcomes. As of November 2018, Cianna Medical operates as a subsidiary of Merit Medical Systems, Inc.

Visual IQ is a leading provider of cross-channel marketing attribution software, established in 2006. The company offers its SaaS-based IQ Intelligence Suite, which delivers in-depth insights into cross-channel marketing performance by analyzing complex data sets. This platform provides actionable recommendations and optimized media plans that enhance the effectiveness of marketing strategies across both online and offline channels, thereby increasing return on investment. Visual IQ utilizes advanced multi-dimensional fractional attribution science and predictive analytics to help marketers identify and capitalize on improvement opportunities. The company's contributions to the field have been recognized through various awards, including The Drum's Digital Trading Award for Best Attribution Solution and the ASPY Award for Best Data or Analytics Solution. Visual IQ is also actively involved in industry organizations, serving on councils and committees related to advertising technology and data analytics.

Cianna Medical, Inc. is a women’s health company focused on innovative solutions for the treatment of early-stage breast cancer. Based in Aliso Viejo, California, the company develops advanced medical technologies designed to enhance breast conservation therapy. Its primary products include SAVI SCOUT, a wire-free radar localization system that assists in accurately locating breast tumors, and SAVI Brachy, which delivers targeted radiation therapy to minimize damage to surrounding healthy tissue. Additionally, Cianna Medical provides BrachyBytes, an e-newsletter that shares insights and expert interviews on breast brachytherapy. Incorporated in 2007, the company aims to expand access to effective treatment options for women diagnosed with breast cancer, improving their chances for successful outcomes. As of November 2018, Cianna Medical operates as a subsidiary of Merit Medical Systems, Inc.

Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

DexCom is a company that develops advanced glucose sensing technologies, primarily focusing on continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1999, the company builds on research from 1967 at the University of Wisconsin regarding implanted glucose sensors. DexCom's CGM systems offer a modern alternative to traditional blood glucose meters, enabling real-time monitoring of glucose levels. The company is also enhancing its systems to integrate with insulin pumps, facilitating automatic insulin delivery. This innovation aims to improve the management of diabetes and enhance the quality of life for patients.

Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.